Every year, Technology Fast 500 ranks the top 500 fastest growing American businesses working in telecommunications, media, technology, and life sciences. Seattle-based Pacific Biomarkers, Inc. recently announced that it has made the list for its fiscal year revenue growth for 2005 to 2009. During this time, the company grew 237 percent, and it contributes its success to expanding its menu of products, pursuing partnerships, treating customers right, and upgrading its infrastructure to handle the growth.
Established in 1989, Pacific Biomarkers offers biomarker laboratory and clinical biomarker services to clients in the diagnostic, biotech, and pharmaceutical industries. Many of these manufacturers use Pacific Biomarker’s products in clinical trials for conditions, such as musculoskeletal diseases, obesity, cardiovascular problems, and diabetes.
Pacific Biomarkers operates under accreditation from the College of American Pathologist, New York State, and Lipid Standardization Program. Under this accreditation, the company provides biomarker assay testing, as well as development. Included in these services are immunogenicity testing, mass spectrometry, and cell-base assays.
CEO Ron Helm responded to the award by crediting three basic factors for the company success. First, Pacific Biomarkers made customer service a priority. This included expanding connections and finding ways to take care of existing clients. Second, the company sought out new technology to keep its infrastructure ready to handle the influx of business. Third, the company aggressively created a presence in the market by forming partnerships.
While many companies succumbed to poor market conditions spawned by a poor economy in 2007 to 2009, Pacific Biomarkers found innovative ways to grow. Many view that as a reward in and of itself. Technology Fast 500 uses information from Form 10-K as well as fiscal reports from the companies in consideration for its award.
For Pacific Biomarkers the growth and the recognition indicate the company is on the right path to continue its growth trend.